Overview

Paediatric Hepatic International Tumour Trial

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
Phase:
Phase 3
Details
Lead Sponsor:
University of Birmingham
Collaborators:
Fundació Institut Germans Trias i Pujol
Medical University of Gdansk
University Hospital Munich
University Hospital Tuebingen
University Hospital, Bonn
University of Kiel
University of Newcastle Upon-Tyne
University of Padova
University of Padua
Treatments:
Carboplatin
Cisplatin
Doxorubicin
Etoposide
Etoposide phosphate
Fluorouracil
Gemcitabine
Irinotecan
Liposomal doxorubicin
Oxaliplatin
Sorafenib
Vincristine